Paragon 2 (FNA) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976in connection with ...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and ...

Shares of Paragon 28, Inc. (NYSE:FNA – Get Free Report) have received a consensus rating of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports.

The Ademi Firm is investigating Paragon 28 (NYSE: FNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our ...

Paragon 28 had a negative net margin of 25.31% and a negative return on equity of 37.90%. The company had revenue of $71.75 million during the quarter, compared to the consensus estimate of $70.81 ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in cash is fair to Paragon 28 ...

ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot ...